Anika Starts New Year With Fidia Acquisition, Direct Sales Plan
This article was originally published in The Gray Sheet
Executive Summary
Anika Therapeutics' acquisition of Fidia Advanced Biopolymers provides a "critical mass" of hyaluronic acid-based products to market in the U.S. alongside its PMA-pending Monovisc single-injection knee osteoarthritis therapy, the firm said